# Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

> **NCT00026312** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1449 (actual)

## Conditions studied

- Localized Resectable Neuroblastoma
- Localized Unresectable Neuroblastoma
- Recurrent Neuroblastoma
- Regional Neuroblastoma
- Stage 4 Neuroblastoma
- Stage 4S Neuroblastoma

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** Dinutuximab
- **DRUG:** Isotretinoin
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Quality-of-Life Assessment
- **BIOLOGICAL:** Sargramostim

## Key facts

- **NCT ID:** NCT00026312
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10-26
- **Primary completion:** 2012-01-12
- **Final completion:** 2025-12-31
- **Target enrollment:** 1449 (ACTUAL)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00026312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00026312, "Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00026312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*